Traws Pharma has made notable advancements in its antiviral programs, particularly with Ratutrelvir for COVID-19. Regulatory engagement and a significant increase in revenue highlight positive progress. However, challenges such as deferred influenza studies and reduced cash reserves present concerns. Overall, highlights slightly outweigh the lowlights, indicating a cautiously optimistic outlook.

Company Guidance

During the second quarter of 2025, Traws Pharma provided guidance on their strategic focus areas, highlighting significant developments in their antiviral and influenza programs. They are advancing ratutrelvir, a ritonavir-free treatment for COVID-19, into Phase II studies, expecting results by the end of 2025, which could tap into a $1.5 billion market opportunity. Ratutrelvir aims to address the limitations of PAXLOVID, which saw a 70% sales increase to $427 million this quarter, by offering a longer treatment duration of 10 days and avoiding drug-drug interactions caused by ritonavir. Traws is also in discussions with BARDA for tivoxavir marboxil's potential inclusion in drug stockpiles for influenza, including bird flu, with recent protocol approvals in Australia and South Korea. Financially, Traws reported a net loss of $0.9 million for the quarter, a significant improvement from the $123.1 million loss in the same period of 2024, due to recognizing $2.7 million in deferred revenue following a licensing agreement termination. The company's cash reserves stood at $13.1 million, down from $21.3 million at the end of 2024.

Strong Progress in Antiviral Development

Traws Pharma has reprioritized its clinical trial plans, advancing Ratutrelvir for COVID treatment, with Phase II study results expected by year-end 2025.

Potential Market Opportunity for Ratutrelvir

Ratutrelvir is targeted to address a $1.5 billion annual market opportunity for individuals ineligible for PAXLOVID, expanding COVID-19 treatment access.

Engagement with Regulatory Authorities

Approval of Phase II bird flu/seasonal flu protocol by Australian and South Korean regulatory authorities, allowing quick study initiation if bird flu incidence rates increase.

Increase in Revenue

Revenue for Q2 2025 was $2.7 million, a significant increase from $57,000 in the same period of 2024, due to deferred revenue recognition from a terminated licensing agreement.

Reduced Net Loss

Net loss for Q2 2025 was $0.9 million compared to $123.1 million in Q2 2024, showing improved financial management.

Traws Pharma (TRAW) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TRAW Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	- / -	-8.81	―	―	―
Aug 14, 2025	2025 (Q2)	- / -0.11	-121.75	99.91% (+121.64)	―
May 15, 2025	2025 (Q1)	- / 2.17	-6	136.17% (+8.17)	―	―
Mar 31, 2025	2024 (Q4)	-9.55 / 2.09	-6	134.83% (+8.09)	―
Nov 14, 2024	2024 (Q3)	-6.25 / -8.81	-5.75	-53.22% (-3.06)	―	―
Aug 15, 2024	2024 (Q2)	-6.25 / -121.75	-5	-2335.00% (-116.75)	―
May 16, 2024	2024 (Q1)	- / -0.28	-7	96.00% (+6.72)	―	―
Apr 01, 2024	2023 (Q4)	-5.88 / -6.00	-7	14.29% (+1.00)	―	―
Nov 14, 2023	2023 (Q3)	-7.25 / -5.75	-6.5	11.54% (+0.75)	―
Aug 10, 2023	2023 (Q2)	-7.81 / -5.00	-4.75	-5.26% (-0.25)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TRAW Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$1.64	$1.62	-1.22%
May 15, 2025	$1.24	$1.10	-11.29%
Mar 31, 2025	$2.40	$2.30	-4.17%
Nov 14, 2024	$5.58	$4.99	-10.57%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Traws Pharma (TRAW) report earnings?

Traws Pharma (TRAW) is schdueled to report earning on Nov 13, 2025, Before Open (Confirmed).

What is Traws Pharma (TRAW) earnings time?

Traws Pharma (TRAW) earnings time is at Nov 13, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TRAW EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing